Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

COMMENT

LETTER

Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al

Russell J Rackley

Journal of Pharmaceutical Sciences 2010, 99 (2): 568-71; author reply 574

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

You are not logged in. Sign Up or Log In to join the discussion.

Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model. Kevin W Garren, Sibtain Rahim, Kennan Marsh, John B Morris Journal of Pharmaceutical Sciences 2010, 99 (2): 626-31

Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals. Jasper van der Lugt, Joep Lange, Anchalee Avihingsanon, Jintanat Ananworanich, Siriporn Sealoo, David Burger, Meena Gorowara, Praphan Phanuphak, Kiat Ruxrungtham Antiviral Therapy 2009, 14 (7): 1001-4

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. Cheri Enders Klein, Yi-Lin Chiu, Walid Awni, Tong Zhu, Renee S Heuser, Thao Doan, Joerg Breitenbach, John B Morris, Scott C Brun, George J Hanna Journal of Acquired Immune Deficiency Syndromes: JAIDS 2007 April 1, 44 (4): 401-10

Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation. Mark W Hull, Marianne Harris, Viviane Lima, Silvia Guillemi, P Richard Harrigan, Julio S G Montaner Journal of Clinical Pharmacology 2009, 49 (2): 155-61

Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation. (no author information available yet) Prescrire International 2007, 16 (90): 148

Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities. Judit Morello, Vincent Soriano, Francisco Blanco, Antonio J Rubio, Inmaculada Jiménez-Nácher, Sonia Rodríguez-Nóvoa Drug Metabolism Letters 2009, 3 (2): 67-9

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. K M L Crommentuyn, B S Kappelhoff, J W Mulder, A T A Mairuhu, E C M van Gorp, P L Meenhorst, A D R Huitema, J H Beijnen British Journal of Clinical Pharmacology 2005, 60 (4): 378-89

Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Manon van der Lee, Gwenda Verweel, Ronald de Groot, David Burger Antiviral Therapy 2006, 11 (4): 439-45

Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily. Reshmie A Ramautarsing, Jasper van der Lugt, Meena Gorowara, Jiratchaya Wongsabut, Chuleeporn Khongpetch, Praphan Phanuphak, Jintanat Ananworanich, Joep M A Lange, David M Burger, Kiat Ruxrungtham, Anchalee Avihingsanon Journal of Acquired Immune Deficiency Syndromes: JAIDS 2012 January 1, 59 (1): 55-8

Make the most of Read.
Download the mobile app.

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Read